Price
No data yet.
Social Signal Score
Analyst Ratings
48 analystsRevenue
$1.24B+213.40%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Renee D. Gala
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,890
- Beta
- 0.32
- Country
- IE
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.00
Financials
Revenue
$1.24B+213.4%Net Income
$-483.40M-514.3%EBITDA
$-234.50M-213.0%Free Cash Flow
$489.90M+173.0%EPS (diluted)
$-7.48-491.6%Shares Outstanding (diluted)
64.70M+6.0%Operating Expenses
$619.80MCash & Debt
$2.86BReturn of Capital
$225.00MRevenue by Segment (annual)
$4.19BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.27B | $-356.15M | $-5.84 |
| 2024 | $4.07B | $560.12M | $9.06 |
| 2023 | $3.83B | $414.83M | $6.55 |
| 2022 | $3.66B | $-224.06M | $-3.58 |
| 2021 | $3.09B | $-328.95M | $-5.51 |
| 2020 | $2.36B | $238.62M | $4.28 |
| 2019 | $2.16B | $523.37M | $9.22 |
| 2018 | $1.89B | $447.10M | $7.45 |
| 2017 | $1.62B | $487.85M | $8.13 |
| 2016 | $1.49B | $396.83M | $6.56 |
| 2015 | $1.32B | $329.54M | $5.38 |
| 2014 | $1.17B | $58.39M | $0.98 |
| 2013 | $872.42M | $216.31M | $3.71 |
| 2012 | $585.98M | $288.59M | $5.09 |
Valuation
JAZZhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-88.00%Social Signal Score
Mentions (36)
- Newsmarketbeat.com·1d ago·Negative
Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance Jazz Pharmaceuticals NASDAQ: JAZZ is counting on new drug launches, pipeline studies and acquisitions to sustain growth across its sleep, epilepsy and oncology businesses, President and CEO Renee Gala said at an investor event.
View source ↗ - Newszacks.com·13d ago·Negative
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
View source ↗ - Newsprnewswire.com·19d ago·Neutral
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences DUBLIN, Nov. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Jefferies London Global Healthcare Conference on Tuesday, November 17, 2026, at 8:00 a.m. ET Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026, at 8:00 a.m.
View source ↗ - Newszacks.com·19d ago·Positive
JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View Jazz Pharmaceuticals beat Q3 2026 revenue and earnings estimates, driven by oncology and rare sleep growth, and raises its full-year sales outlook.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
Jazz Pharmaceuticals Q3 Earnings Call Highlights Jazz Pharmaceuticals NASDAQ: JAZZ reported record third-quarter revenue of $1.24 billion, up 10% from a year earlier, and raised its full-year 2026 revenue outlook as growth in its sleep and oncology businesses offset product-specific pressures and continued investment in its pipeline.
View source ↗ - Newszacks.com·20d ago·Neutral
Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·20d ago·Negative
Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates Jazz Pharmaceuticals (JAZZ) came out with a quarterly loss of $3.88 per share versus the Zacks Consensus Estimate of a loss of $4.09. This compares to earnings of $8.13 per share a year ago.
View source ↗ - Newsprnewswire.com·20d ago·Neutral
…s in 3Q26 – – Closed Actio acquisition, adding ABS-1230 (JZP6979) to rare epilepsy portfolio – DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2026 (3Q26). "Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.
View source ↗ - Newsprnewswire.com·20d ago·Neutral
…tinued development of novel therapies for rare brain cancers For U.S. media and investors only DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that clinical and preclinical research from its neuro-oncology portfolio will be presented at the upcoming 2026 Society for Neuro-Oncology (SNO) Annual Meeting, taking place November 12-15 in Philadelphia. Key highlights include: The confirmatory Phase 3 ACTION trial evaluating Modeyso® (dordaviprone), formerly…
View source ↗ - Newsfool.com·26d ago·Neutral
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine Jazz Pharmaceuticals' financial results are improving. The company's oncology business could push sales and earnings even higher.
View source ↗ - Newsprnewswire.com·30d ago·Neutral
…e risk of death by 24% versus trastuzumab plus chemotherapy For U.S. media and investors only DUBLIN, Oct. 23, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without Tevimbra® (tislelizumab-jsgr), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenoc…
View source ↗ - Newsprnewswire.com·34d ago·Neutral
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026 DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m.
View source ↗ - Newszacks.com·37d ago·Neutral
Is JAZZ Stock Still a Smart Way to Play Medical Cannabis? Jazz Pharmaceuticals offers a differentiated medical cannabis play, with Epidiolex sales growth and a diversified portfolio offset by pipeline setbacks and earnings pressures.
View source ↗ - Newsseekingalpha.com·38d ago·Neutral
…ng The Earnings Story Jazz Pharmaceuticals is transforming beyond oxybate reliance, with diversified growth across sleep medicine, epilepsy, and oncology portfolios. JAZZ delivered robust Q2 2026 results: $1.21B revenue (+16% YoY), strong gross margins (92.1% non-GAAP), and raised FY guidance to $4.60–$4.75B. Ziihera's FDA approval for 1L HER2-positive GEA marks a major oncology expansion, with clinical data showing a significant survival benefit over standard of care.
View source ↗ - Newsmarketbeat.com·63d ago·Neutral
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B Jazz Pharmaceuticals NASDAQ: JAZZ executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.
View source ↗ - Newsmarketbeat.com·63d ago·Neutral
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Get Jazz Pharmaceuticals alerts:Sign UpZiihera Data and Development Plans An unnamed Jazz executive said zanidatamab, marketed as Z…
View source ↗ - Newsfool.com·65d ago·Positive
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? Jazz paid $820 million up front to acquire Actio Biosciences. Actio shareholders could receive another $500 million in milestone payments.
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·73d ago·Positive
Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Jazz Pharmaceuticals plc (JAZZ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Jazz Pharmaceuticals plc (JAZZ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·81d ago·Neutral
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 1:30 p.m.
View source ↗ - Newszacks.com·81d ago·Neutral
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report? Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·82d ago·Neutral
JAZZ Rises on Updated OS Results From Gastric Cancer Study Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.
View source ↗ - Newsprnewswire.com·83d ago·Neutral
…are Data submitted for presentation in fourth quarter 2026 For U.S. media and investors only DUBLIN, Aug. 31, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial showing that Ziihera® (zanidatamab-hrii) in combination with chemotherapy demonstrated statistically significant and clinically meaningful improvements in OS compared with trastuzumab plus chemotherapy as first-line trea…
View source ↗ - Newsprnewswire.com·87d ago·Positive
…illion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the…
View source ↗ - Newszacks.com·88d ago·Positive
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.
View source ↗ - Newsbenzinga.com·88d ago·Negative
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals The U.S. Food and Drug Administration (FDA), on Tuesday, approved Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) two Ziihera-containing combination regimens as first-line treatments for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.
View source ↗ - Newsprnewswire.com·88d ago·Positive
… $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases DUBLIN, Aug. 26, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") to qualified …
View source ↗ - Newsseekingalpha.com·89d ago·Positive
Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA Transcript Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA Transcript
View source ↗ - Newsmarketbeat.com·89d ago·Neutral
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA Jazz Pharmaceuticals NASDAQ: JAZZ outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic gastroesophageal adenocarcinoma, or GEA.
View source ↗ - Newsprnewswire.com·89d ago·Negative
…Company to host investor webcast on Aug. 25 at 4:30 p.m. ET For U.S. media and investors only DUBLIN, Aug. 25, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and fluoro…
View source ↗ - Newsseekingalpha.com·102d ago·Neutral
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout Jazz Pharmaceuticals acquires Actio Biosciences for $820 million upfront, targeting rare KCNT1+ epilepsy with ABS-1230, a registrational-stage precision therapy. JAZZ delivered record Q2 2026 revenues of ~$1.2 billion, with strong year-on-year growth in key assets like Xywav (+13%) and Zepzelca (+42%). Despite a competitive narcolepsy landscape and $4.4 billion in debt, JAZZ's diversified portfolio, robust cash positio
View source ↗ - Newsreuters.com·104d ago·Positive
Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio Jazz Pharmaceuticals said on Monday it would buy privately held Actio Biosciences in a deal valued at up to $1.32 billion, adding an experimental treatment for a rare inherited form of epilepsy that has no approved therapies.
View source ↗ - Newsprnewswire.com·104d ago·Negative
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction includes $820 million upfront payment DUBLIN and SAN DIEGO, Aug. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have en
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $6.96 per share
Typical surprise +1.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$-3.88 vs $-4.03beat
- Mon, Aug 3$5.71 vs $6.18miss
- Tue, May 5$6.34 vs $4.64beat
- Tue, Feb 24$6.64 vs $6.52beat
- Wed, Nov 5$8.13 vs $5.95beat
- Tue, Aug 5$-8.25 vs $-6.12miss
Estimates and results for JAZZ via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by JAZZ officers and directors.
- Bought
- —
- Sold
- $50.3m
0 trades
31 trades
- Cozadd Bruce Csold
- Cozadd Bruce Csold
- Cozadd Bruce Csold
- Cozadd Bruce Csold
- Carr Patriciasold
- Carr Patriciasold
- Gala Renee Dsold
- Cozadd Bruce Csold
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (32d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (24d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (24d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (24d later)Sell$1,001 - $15,000
- Thomas Suozzihouse · NY03 · disclosed Oct 14, 2022 (18d later)Sell$1,001 - $15,000
- Thomas Suozzihouse · NY03 · disclosed Nov 5, 2021 (17d later)Buy$1,001 - $15,000
- Bill Floreshouse · TX17 · disclosed Aug 12, 2019 (28d later)Buy$15,001 - $50,000
- Carlos Curbelohouse · FL26 · disclosed Sep 25, 2018 (28d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
